Evidence map›Paper›PMID 33815279›Full record

ArticleFrontiers in endocrinology2021

Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease.

Amit Akirov, Vincent Larouche, Ilan Shimon, Sylvia L Asa, Ozgur Mete, Anna M Sawka, Fred Gentili, Shereen Ezzat

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Perioperative Management of a Patient With Cushing Disease.Journal of the Endocrine Society · 2022
    Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Amit AkirovDepartment of Endocrine Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Vincent LaroucheDepartment of Endocrine Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
Ilan ShimonInstitute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel.
Sylvia L AsaDepartment of Pathology, University Hospitals, Cleveland, Case Western Reserve University, Cleveland, OH, United States.
Ozgur MeteDepartment of Pathology, University Health Network, University of Toronto, Toronto, ON, Canada.
Anna M SawkaDivision of Endocrinology, University Health Network and University of Toronto, Toronto, ON, Canada.
Fred GentiliDivision of Neurosurgery, Toronto Western Hospital, University Health Network and Department of Surgery, University of Toronto, Toronto, ON, Canada.
Shereen EzzatDepartment of Endocrine Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.
University of Toronto · CACase Western Reserve University · USPrincess Margaret Cancer Centre · CARabin Medical Center · ILToronto Western Hospital · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Glucocorticoid excess in Cushing disease (CD) leads to negative feedback suppression, resulting in Crooke's hyaline change (CC) of nontumorous pituitary corticotrophs. We aimed to determine the predictive value of CC of nontumorous corticotrophs in CD. Methods: The retrospective chart review study included patients with clinical, biochemical, radiologic and outcome data and evaluable histopathology specimens from pituitary surgery for CD. The main outcome was remission of CD, defined by clinical features, biochemical testing, and corticosteroid dependency. Results: Of 144 CD patients, 60 (50 women, mean age 43.6±14) had clinical follow-up, biochemical data and histopathology specimens that included evaluable nontumorous adenohypophysis. Specimens from 50 patients (83.3%) demonstrated CC in nontumorous corticotrophs, and 10 (16.7%) had no CC (including 3 with corticotroph hyperplasia). One patient with CC was lost to follow-up and one without CC had equivocal outcome results. During a mean (SD) follow-up period of 74.9 months (61.0), recurrent or persistent disease was documented in 18 patients (31.0%), while 40 (69.0%) were in remission. In patients with CC, the remission rate was 73.5% (95% CI, 59.7%-83.7%) (36/49), whereas it was 44.4% (95% CI, 18.9%-73.3%) (4/9) in patients with no CC. The combination of serum cortisol >138 nmol/L within a week of surgery coupled with absence of nontumorous CC greatly improved the prediction of recurrent or persistent disease. Conclusions: CC of nontumorous corticotrophs was observed in 83% of patients with CD, and most patients with CC experienced remission. Absence of CC in nontumorous corticotrophs may serve as a predictor of reduced remission in patients with CD.

Indexed as

HyalinAdultCorticotrophsFemaleHumansMaleMiddle AgedPituitary ACTH HypersecretionPituitary GlandRetrospective Studiescorticotroph tumorCrooke's changesCushing diseasepituitary tumor regrowth and recurrencepituitary tumors

Identifiers

PMID33815279
PMCPMC8013723
OpenAlexW3137988260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.